Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Endocrinology, Third Affiliated Hospital of Wenzhou Medical University, Ruian, China.
Front Endocrinol (Lausanne). 2020 Oct 16;11:528146. doi: 10.3389/fendo.2020.528146. eCollection 2020.
Adverse maternal outcomes and perinatal complications are associated with overt and subclinical maternal hypothyroidism. It is not clear whether these complications also occur in women with isolated hypothyroxinemia during pregnancy. The aim of this study was to evaluate the effects of isolated hypothyroxinemia on maternal and perinatal outcomes during pregnancy. This study included data from 2,864 pregnant women in the first trimester (67 women with isolated hypothyroxinemia, 784 euthyroid women) and the second trimester (70 women with isolated hypothyroxinemia, 1,943 euthyroid women) of pregnancy. Maternal serum samples were collected in the first and second trimesters to examine thyroid hormone concentration. Hypothyroxinemia was defined as a normal maternal thyroid-stimulating hormone concentration with a low maternal free thyroxine concentration and negative thyroid autoantibodies. The following maternal outcomes were recorded: gestational hypertension, gestational diabetes mellitus, placenta previa, placental abruption, prelabor rupture of membranes, and premature delivery. Perinatal outcomes, including fetal growth restriction, fetal distress, low birth weight, intrauterine fetal death, and malformation. The incidence of adverse pregnancy outcomes and perinatal complications was compared between women in the first trimester and second trimester with isolated hypothyroxinemia. There were no significant differences in the incidence rates of adverse maternal outcomes and perinatal complications between patients in the first and second trimesters with isolated hypothyroxinemia. The results of this study indicate that isolated hypothyroidism does not increase the incidence of adverse maternal outcomes and perinatal complications.
母体不良结局和围产儿并发症与显性和亚临床型母体甲状腺功能减退症相关。但目前尚不清楚孤立性妊娠期间甲状腺素血症患者是否也会出现这些并发症。本研究旨在评估孤立性妊娠期间甲状腺素血症对母体和围产儿结局的影响。
该研究纳入了 2864 名孕早期(67 名孤立性甲状腺素血症患者,784 名甲状腺功能正常患者)和孕中期(70 名孤立性甲状腺素血症患者,1943 名甲状腺功能正常患者)的孕妇数据。在孕早期和孕中期采集母体血清样本,以检测甲状腺激素浓度。孤立性甲状腺素血症定义为正常的母体促甲状腺激素浓度,伴低母体游离甲状腺素浓度和阴性甲状腺自身抗体。记录以下母体结局:妊娠期高血压、妊娠期糖尿病、前置胎盘、胎盘早剥、胎膜早破和早产。围产儿结局包括胎儿生长受限、胎儿窘迫、低出生体重儿、宫内胎儿死亡和畸形。比较孕早期和孕中期孤立性甲状腺素血症患者的不良妊娠结局和围产儿并发症发生率。
孤立性甲状腺素血症患者在孕早期和孕中期的不良母体结局和围产儿并发症发生率无显著差异。
本研究结果表明,孤立性甲状腺素血症不会增加不良母体结局和围产儿并发症的发生率。